Despite strong preclinical rationale supporting the use of mTORC1/2 inhibition in STK11-deficient lung cancer, clinical activity of vistusertib was clearly disappointing, even in cancers with concomitant KRAS mutations. This evidence concerns the gene KRAS and lung carcinoma.